ClinicalTrials.gg
CompletedNCT01960114Updated Jul 10, 2015Results posted

Study of Long-Acting Acetaminophen in Postoperative Dental Pain

A Phase 2 interventional study of Acetaminophen ER and Placebo in Dental Pain, sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.. Completed at 1 site in United States. Open to participants aged 17 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-07-10.

Sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. (formerly part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
403
Allocation
Randomized
Ages
17 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Toothache with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Toothache · United States.

Enrollment
7th of 50
403 · median 194
Started
2013
with 2 others
Phase 2
20 of 54
none open now
Registered
29th of 54
by date
Lead sponsor
2 of 54
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.

Among the 54 studies in Toothache with a site in United States, this one is the 7th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2013, is one of 20 in phase 2, and was the 29th registered.

Toothache

142 studies on the registry are indexed under Toothache; 28 are open to participants now.

Browse Toothache studies →

Open to participants now

6 of the 54 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 17 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Toothache with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of acetaminophen ER 1500 mg (two 750 mg tablets) over 10 to 12 hours in the dental pain model following third molar extraction(s) and to evaluate the pharmacokinetics of acetaminophen ER 1500 mg (two 750 mg tablets) in a sub-group of subjects.

03

Conditions studied

  • Dental Pain

Keywords

  • Acetaminophen
  • Paracetamol Analgesics
  • Analgesics
  • Non-Narcotic Pain
  • Postoperative Pain
  • Antipyretics Dental Surgery
  • Third molar extraction
04

Who can participate

Ages eligible
17 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be at least 17 and less than 46 years of age
  • Must weigh at least 100 lbs with a of at least 18 and less than 30
  • Scheduled to undergo surgical extraction of one impacted third molar from the lower jaw. The third molar from the upper jaw from the same side may also be removed.
  • Experiencing moderate to severe pain after extraction of third molars.

Exclusion criteria

Exclusion Criteria:

  • Cannot be allergic to acetaminophen (Tylenol) or any non-steroidal anti-inflammatory drugs (e.g., Motrin, Advil, Aleve, Naproxen).
  • Cannot be pregnant (or planning to be pregnant) or nursing a baby
  • Unable to swallow whole large tablets or caplets.
  • Cannot have any other medical conditions that the investigator feels may compromise your safety or the study results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
403 participants (actual)

Study arms

  • Experimental
    Acetaminophen ER

    Drug: Acetaminophen ER

  • Placebo comparator
    Placebo

    Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo

    Drug: Placebo

Interventions

  • Single dose (2 tablets) Acetaminophen ER 750 mg

  • DrugPlacebo

    Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo

06

What researchers measure

Primary outcomes

  1. Time Weighted Sum of Pain Intensity Difference (PID) Over 10 Hours (SPID 0-10)

    Time weighted sum of pain intensity difference scores from baseline over 10 hours. Pain intensity was evaluated using a 0-10 numerical rating scale (NRS) where 0 = no pain and 10 = very severe pain. SPID 0-10 = 0.25 x (PID at 15 min + PID at 30 min + PID at 45 min + PID at 60 min + PID at 75 min + PID at 90 min) + 0.5 x (PID at 120 min) + PID at 3 h + PID at 4 h + PID at 5 h + PID at 6 h + PID at 7 h + PID at 8 h + PID at 9 h + PID at 10 h.

    Time frame: 10 Hours

Secondary outcomes

  1. Time to Confirmed First Perceptible Pain Relief

    Minutes until confirmed first perceptible pain relief was achieved. Stopwatch was started after the subject took the study medication. The subject was instructed to stop the stopwatch when they first began to feel any pain relief. The first perceptible pain relief was confirmed if the subject also stopped the second stopwatch indicating meaningful pain relief.

    Time frame: Within 12 Hours

  2. Time to Meaningful Pain Relief

    Minutes until meaningful pain relief was achieved. Stopwatch was started after the subject took the study medication. The subjects were instructed to stop the stopwatch when the relief from the starting pain was meaningful to them.

    Time frame: Within 12 Hours

  3. Duration of Pain Relief

    Minutes until rescue medication was given.

    Time frame: Within 12 Hours

  4. Patient Global Evaluation

    Patient Assessment of the pain medication - Number of subjects rating the medication they received as a pain reliever on a score of 0-4, where 0=poor, 1=fair, 2=good, 3=very good, 4=excellent.

    Time frame: 12 Hours

07

Results

Posted Jun 10, 2015

Participant flow

Participant flow — Overall Study
MilestonePlaceboACE ER 1500 mg
Started134269
Completed133268
Not completed11
Withdrew: Adverse event10
Withdrew: Could not swallow study medication01

Outcome measures

PrimaryTime Weighted Sum of Pain Intensity Difference (PID) Over 10 Hours (SPID 0-10)

Time weighted sum of pain intensity difference scores from baseline over 10 hours. Pain intensity was evaluated using a 0-10 numerical rating scale (NRS) where 0 = no pain and 10 = very severe pain. SPID 0-10 = 0.25 x (PID at 15 min + PID at 30 min + PID at 45 min + PID at 60 min + PID at 75 min + PID at 90 min) + 0.5 x (PID at 120 min) + PID at 3 h + PID at 4 h + PID at 5 h + PID at 6 h + PID at 7 h + PID at 8 h + PID at 9 h + PID at 10 h.

Time frame:
10 Hours
Reported as:
Least squares mean · units on a scale
Time Weighted Sum of Pain Intensity Difference (PID) Over 10 Hours (SPID 0-10)
units on a scalePlaceboACE ER 1500 mg
Time Weighted Sum of Pain Intensity Difference (PID) Over 10 Hours (SPID 0-10)5.745 ± 2.505630.986 ± 1.8951
Statistical analysis
  • Placebo vs ACE ER 1500 mg · ANOVA · p = <0.001 (The significance threshold level was 0.05 (two-sided).) · Least squares mean difference: 25.241 · 95% CI 19.669 to 30.813Treatment and baseline pain categorical score were factors.
SecondaryTime to Confirmed First Perceptible Pain Relief

Minutes until confirmed first perceptible pain relief was achieved. Stopwatch was started after the subject took the study medication. The subject was instructed to stop the stopwatch when they first began to feel any pain relief. The first perceptible pain relief was confirmed if the subject also stopped the second stopwatch indicating meaningful pain relief.

Time frame:
Within 12 Hours
Reported as:
Median · Minutes
Time to Confirmed First Perceptible Pain Relief
MinutesPlaceboACE ER 1500 mg
Time to Confirmed First Perceptible Pain ReliefNA (NA to NA)26.817 (23.683 to 29.950)
Statistical analysis
  • Placebo vs ACE ER 1500 mg · Wilcoxon test, from SAS PROC LIFETEST · p = <0.001 (The significance threshold level was 0.05 (two-sided). p-Values are based on the Wilcoxon test from PROC LIFETEST that compared survival curves.)
SecondaryTime to Meaningful Pain Relief

Minutes until meaningful pain relief was achieved. Stopwatch was started after the subject took the study medication. The subjects were instructed to stop the stopwatch when the relief from the starting pain was meaningful to them.

Time frame:
Within 12 Hours
Reported as:
Median · Minutes
Time to Meaningful Pain Relief
MinutesPlaceboACE ER 1500 mg
Time to Meaningful Pain ReliefNA (NA to NA)84.675 (66.333 to 120.633)
Statistical analysis
  • Placebo vs ACE ER 1500 mg · Wilcoxon test, from SAS PROC LIFETEST · p = <0.001 (The significance threshold level was 0.05 (two-sided). p-Values are based on the Wilcoxon test from PROC LIFETEST that compared survival curves.)
SecondaryDuration of Pain Relief

Minutes until rescue medication was given.

Time frame:
Within 12 Hours
Reported as:
Median · Minutes
Duration of Pain Relief
MinutesPlaceboACE ER 1500 mg
Duration of Pain Relief106.5 (99.000 to 132.000)NA (NA to NA)
Statistical analysis
  • Placebo vs ACE ER 1500 mg · Log Rank · p = <0.001 (The significance threshold level was 0.05 (two-sided). p-Values are based on the log-rank test from PROC LIFETEST that compared survival curves.)
SecondaryPatient Global Evaluation

Patient Assessment of the pain medication - Number of subjects rating the medication they received as a pain reliever on a score of 0-4, where 0=poor, 1=fair, 2=good, 3=very good, 4=excellent.

Time frame:
12 Hours
Reported as:
Number · percentage of participants
Patient Global Evaluation
percentage of participantsPlaceboACE ER 1500 mg
Poor (0)63.218.3
Fair (1)9.011.2
Good (2)8.314.6
Very Good (3)12.835.8
Excellent (4)6.820.1
Statistical analysis
  • Placebo vs ACE ER 1500 mg · Cochran-Mantel-Haenszel · p = 0.001 (The significance threshold level was 0.05 (two-sided).)Used row-mean scores based on Cochran-Mantel-Haenszel test was stratified by baseline categorical pain score.

Adverse events

Collected over Day 5-7 for non-serious adverse events, until 30 days after the last study site visit for serious adverse events.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/134 (0%)14/134 (10.4%)
ACE ER 1500 mg—0/268 (0%)26/268 (9.7%)
Most frequent other events
Most frequent other events
EventPlaceboACE ER 1500 mg
NauseaGastrointestinal disorders14/13426/268

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboACE ER 1500 mgTotal
Mean19.6 ± 2.6619.5 ± 2.8219.6 ± 2.77
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboACE ER 1500 mgTotal
Female72143215
Male62126188
Region of Enrollment
Region of Enrollment(participants)PlaceboACE ER 1500 mgTotal
USA134269403
08

Study locations

1 site
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 1 year 2 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2013
First posted
Oct 10, 2013
Start
Oct 2013
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results delay requested
Mar 23, 2015
Results first posted
Jun 10, 2015
Last update
Jul 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01960114
Responsible party
Sponsor
First posted
Oct 10, 2013
Start date
Oct 2013
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Jun 10, 2015
Last update
Jul 10, 2015

Study contacts

McNeil Study Director
study director · McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion